00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
17:58 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Plinabulin meets in Phase III for chemotherapy-induced neutropenia

BeyondSpring Inc. (NASDAQ:BYSI) reported interim data on Dec. 6 showing that plinabulin (BPI-2358) met the primary endpoint in the Phase III portion of the Phase II/III Protective-1 trial to treat chemotherapy-induced neutropenia in patients with...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
16:15 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture studies suggest inhibiting IKK or its scaffold protein NEMO in combination with inhibition of MC-1 could help treat STK11-deficient lung cancer. In a human STK11-deficient lung cancer cell line, the...
21:08 , Aug 2, 2018 |  BC Extra  |  Company News

Management tracks: Omeros, EdiGene

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
22:00 , May 18, 2018 |  BC Extra  |  Company News

Management tracks: Seattle Genetics, SurModics

Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) said CMO Jonathan Drachman has stepped down. He is succeeded by Roger Dansey, who was therapeutic area head for late-stage oncology at Merck & Co. Inc. (NYSE:MRK). Medical...
22:50 , Mar 27, 2018 |  BC Extra  |  Company News

Management Tracks: CRISPR, UK Research and Innovation

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) said Chief Legal Officer Tyler Dylan-Hyde will retire. The company hired Shelby Walker as head of IP. She was general counsel at Ginkgo Bioworks Inc. (Boston, Mass.). UK...